Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13157-62. doi: 10.1073/pnas.1410785111. Epub 2014 Aug 25.

RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection.

Author information

1
Department of Bioengineering.
2
Department of Bioengineering, Department of Applied Physics, and Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305 quake@stanford.edu.

Abstract

Latent viral infection is a persistent cause of human disease. Although standard antiviral therapies can suppress active viral replication, no existing treatment can effectively eradicate latent infection and therefore a cure is lacking for many prevalent viral diseases. The prokaryotic immune system clustered regularly interspaced short palindromic repeat (CRISPR)/Cas evolved as a natural response to phage infections, and we demonstrate here that the CRISPR/Cas9 system can be adapted for antiviral treatment in human cells by specifically targeting the genomes of latent viral infections. Patient-derived cells from a Burkitt's lymphoma with latent Epstein-Barr virus infection showed dramatic proliferation arrest and a concomitant decrease in viral load after exposure to a CRISPR/Cas9 vector targeted to the viral genome.

KEYWORDS:

genome editing; herpes virus; latency

PMID:
25157128
PMCID:
PMC4246930
DOI:
10.1073/pnas.1410785111
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center